Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Alaunos Therapeutics ( (TCRT) ) is now available.
On June 20, 2025, Alaunos Therapeutics, Inc. entered into a securities purchase agreement to issue and sell shares of common stock and pre-funded warrants in a registered direct offering, which closed on June 24, 2025. The proceeds from this offering are intended for general corporate purposes, including capital expenditures and working capital, potentially impacting the company’s operational capabilities and market positioning.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Alaunos Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies and treatments. The company primarily engages in the research and development of therapeutic products aimed at addressing unmet medical needs.
Average Trading Volume: 498,521
Technical Sentiment Signal: Sell
Current Market Cap: $7.39M
Find detailed analytics on TCRT stock on TipRanks’ Stock Analysis page.